Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors

Dr. David S. Hong presents the preliminary Phase 1 results on RMC-9805, a first-in-class, oral, RAS(ON) G12D-selective inhibitor, highlighting its promising safety, pharmacokinetics, and early antitumor activity in patients with KRAS G12D-mutant pancreatic ductal adenocarcinoma (PDAC), with further dose optimization and combination studies underway.